By DrBayer.com Editorial Team
Low testosterone is not diagnosed by a quiz, a single blood number, or an ad that promises to “boost” your levels. It’s diagnosed through a specific clinical process: a symptom and medical history review, a physical exam, and two separate early-morning total testosterone blood tests taken on different days. A booster ad can’t do any of that — it isn’t built to, because it’s selling a product, not running a diagnostic pathway. Here’s what the actual evaluation looks like, and where it diverges from what online marketing implies.
Why a Booster Ad Isn’t Answering the Clinical Question
An ad for a testosterone “booster” supplement is answering a commercial question: will you click and buy. It isn’t equipped to answer the clinical question, which is whether your testosterone is actually low enough, and your symptoms consistent enough, to meet the threshold clinicians use. Over-the-counter boosters are regulated as dietary supplements, not as drugs, and don’t require the lab confirmation a real diagnosis does. A symptom checklist that nudges you toward a purchase is a marketing funnel, not an evaluation — a distinction worth sitting with before spending money on the premise that you already know what’s going on.
The Clinical Evaluation Pathway
Symptom and Medical History Review
The process starts with a conversation, not a test. A clinician will ask about symptoms associated with low testosterone — reduced sex drive, erectile changes, persistent fatigue, loss of muscle mass, mood changes, or reduced body hair — along with your broader medical history: existing conditions, medications, and risk factors such as diabetes, obesity, chronic opioid use, or a history of chemotherapy or testicular radiation, all of which raise the likelihood of testosterone deficiency even without classic symptoms.
Physical Examination
A physical exam checks for signs consistent with hormonal problems, alongside other findings relevant to men’s health. Symptoms and a low lab number on their own aren’t enough in either direction — the exam and history build the clinical picture the lab work is then checked against, not a formality that precedes it.
Laboratory Testing: Two Morning Blood Draws
This is the step a booster ad skips entirely. The American Urological Association’s 2024 Testosterone Deficiency Guideline recommends a total testosterone level below 300 ng/dL, measured on two separate occasions, both drawn in the early morning, as a reasonable cutoff supporting a diagnosis. The Endocrine Society’s guideline follows the same core structure — an initial morning total testosterone measurement, confirmed by a repeat morning measurement — though it frames the diagnosis around an “unequivocally low” level rather than anchoring to the identical numeric cutoff the AUA uses. Testosterone follows a natural daily rhythm, so an afternoon draw can read artificially low even in a man with normal levels. Both guidelines are also explicit that a diagnosis requires a confirmed low level and consistent symptoms or signs together — neither one alone is considered diagnostic.
Follow-Up Testing When Testosterone Is Confirmed Low
If two morning draws confirm a low level, the AUA guideline calls for measuring luteinizing hormone (LH), which helps distinguish whether the issue originates in the testes or further upstream, in the pituitary or hypothalamus. Prolactin is checked as part of this same follow-up workup, and persistently high prolactin with no clear cause prompts further endocrine evaluation. For men over 40 being considered for testosterone therapy, PSA is measured beforehand to help exclude a prostate cancer diagnosis.
A Confirmed Diagnosis Isn’t the Same as Being a Candidate for Treatment
This is where the clinical question and the marketing question diverge most. Prescription testosterone is FDA-approved to treat testosterone deficiency caused by specific medical conditions affecting the testes, pituitary gland, or hypothalamus. Its use for testosterone decline that’s simply a function of aging has historically carried a “Limitation of Use” notation on the label, reflecting that benefit and safety for that specific population haven’t been formally established in the same way.
Before starting therapy, the AUA guideline also calls for measuring hemoglobin and hematocrit and counseling patients on the associated risk of polycythemia (an excess of red blood cells) — one more reason “diagnosed” and “ready to start treatment” are two separate clinical steps, not one.
The label itself has also changed recently, which matters if you’re reading older content on this topic. On February 28, 2025, the FDA recommended removing the boxed warning linking testosterone products to cardiovascular risk, based on results from the TRAVERSE trial, while adding a new class-wide warning about increased blood pressure based on separate post-market studies. As of that update, the age-related “Limitation of Use” language was retained. Reporting from mid-2026 indicates the Department of Health and Human Services has since proposed removing that limitation as well, citing the same trial data — but that change was still under review at the time of this writing, not finalized. If you’re comparing this to older articles elsewhere, the cardiovascular warning they may describe is no longer current.
Fertility Is Part of This Conversation
The AUA guideline is specific here: men with testosterone deficiency who are interested in fertility should have a reproductive health evaluation before starting treatment, and testosterone therapy should not be prescribed to men who are currently trying to conceive. That’s because externally supplied testosterone suppresses the body’s own hormonal signaling to the testes, which can reduce sperm production — a long-term effect the guideline says should be discussed directly with any patient interested in future fertility, with options like human chorionic gonadotropin available for men who want to preserve it. Fertility status doesn’t change whether testosterone is low; it changes which treatment path makes sense.
Where Enhancement Marketing Diverges from Medical Care
Much of what’s advertised under the “low-T” or “testosterone optimization” banner online is aimed at performance or lifestyle enhancement rather than treatment of a diagnosed medical condition — two different premises that get blended together in marketing copy. A diagnosis of testosterone deficiency is a clinical finding, built on the pathway above. “Optimization” marketing, by contrast, often targets men whose levels may be entirely normal, using symptom language broad enough to apply to almost anyone who’s tired or stressed. Recognizing which conversation you’re actually having — a medical evaluation or a sales pitch — is most of the work.
What to Do With This Information
If your symptoms line up with what’s described here, the useful next step is reading the primary evidence and preparing specific questions for a clinician — not comparing products. Worth asking directly: has testosterone actually been measured twice, in the morning, on separate days; what was LH; and does the recommended path match a confirmed diagnosis rather than a symptom pattern alone. A comparison of treatment options only makes sense once that groundwork is done.
For related context on how online tools and marketing claims differ from an actual clinical evaluation, see our coverage of what a sexual-health quiz result can’t diagnose and how hormonal health changes with age. Men researching the “Brazilian Hardening Secret” protocol, which includes Tongkat Ali marketed for testosterone-modulating effects, may find it useful context that our review of that protocol addresses herbal ingredient claims specifically — a different question from the diagnostic pathway covered here.